Journal article
Authors list: Heinz, Amadeus T.; Calkoen, Friso G. J.; Derbich, Alexander; Miltner, Lea; Seitz, Christian; Doering, Michaela; Braun, Christiane; Atar, Daniel; Schumm, Michael; Heubach, Florian; Arendt, Anne- Marie; Schulz, Ansgar; Schuster, Friedhelm R.; Meisel, Roland; Strahm, Brigitte; Finke, Juergen; Heineking, Beatrice; Stetter, Susanne; Silling, Gerda; Stachel, Daniel; Gruhn, Bernd; Debatin, Klaus-Michael; Foell, Juergen; Schulte, Johannes H.; Woessmann, Wilhelm; Mauz-Koerholz, Christine; Tischer, Johanna; Feuchtinger, Tobias; Handgretinger, Rupert; Lang, Peter
Publication year: 2023
Pages: 2080-2090
Journal: Haematologica
Volume number: 108
Issue number: 8
ISSN: 0390-6078
eISSN: 1592-8721
Open access status: Gold
DOI Link: https://doi.org/10.3324/haematol.2022.281996
Publisher: Ferrata Storti Foundation
Abstract:
Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability of this therapy is hampered by laborious production methods. In this study we describe the in-house production of VST in a closed system (CliniMACS Prodigy & REG; system, Miltenyi Biotec). In addition, we report the efficacy in 26 patients with viral disease following hematopoietic stem cell transplantation in a retrospective analysis (adenovirus, n=7; cytomegalovirus, n=8; Epstein-Barr virus, n=4; multi-viral, n=7). The production of VST was successful in 100% of cases. The safety profile of VST therapy was favorable (n=2 grade 3 and n=1 grade 4 adverse events; all three were reversible). A response was seen in 20 of 26 patients (77%). Responding patients had a significantly better overall survival than patients who did not respond (P<0.001). Virus-specific symptoms were reduced or resolved in 47% of patients. The overall survival of the whole cohort was 28% after 6 months. This study shows the feasibility of automated VST production and safety of application. The scalability of the CliniMACS Prodigy & REG; device increases the accessibility of VST treatment.
Citation Styles
Harvard Citation style: Heinz, A., Calkoen, F., Derbich, A., Miltner, L., Seitz, C., Doering, M., et al. (2023) Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation, Haematologica, 108(8), pp. 2080-2090. https://doi.org/10.3324/haematol.2022.281996
APA Citation style: Heinz, A., Calkoen, F., Derbich, A., Miltner, L., Seitz, C., Doering, M., Braun, C., Atar, D., Schumm, M., Heubach, F., Arendt, A., Schulz, A., Schuster, F., Meisel, R., Strahm, B., Finke, J., Heineking, B., Stetter, S., Silling, G., ...Lang, P. (2023). Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation. Haematologica. 108(8), 2080-2090. https://doi.org/10.3324/haematol.2022.281996
Keywords
3RD-PARTY DONORS; ADENOVIRUS INFECTIONS; ADOPTIVE TRANSFER; CYTOMEGALOVIRUS; EBV; EPSTEIN-BARR-VIRUS; GANCICLOVIR; LYMPHOPROLIFERATIVE DISEASE
